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increase. We excluded “plasma-derived blood products” that has different pricing 
schemes for the cases they get an exchange rate related increase and also excluded 
the price corrections. Price increase reasons were grouped as defined in the current 
decree. We calculated mean percentage of price increases in overall and in original 
vs. generic, import vs. locally manufactured, products below and above 6.79 TL pack 
price (local definition of cheap products) and ATC1 level subgroups. Results: 606 
products and 274 molecules had price increase in 2013. The most frequent reasons 
for price increase were related critical product status (110 increases), increase in 
reference price (105 increases) and due to the rule of getting the highest reference 
for delisted or non-reimbursed products (89 increases). The average rate of price 
increases was 23.1%. 57% of the price increases were applied to imported products 
compared with 43% locally manufactured ones. Average rate of price increase in 
original and generic products were 24% and 21% respectively. Products with ex-
factory price above 6.79 TL had more price increase compared with cheap prod-
ucts. The highest rate of price increases were in ATC1 groups A and B (81 increases 
each) ConClusions: With the pricing policy change in 2013, price increases were 
possible in Turkey for products from different groups.
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objeCtives: In many countries there is an ongoing debate about pharmaceutical 
pricing. Especially in Germany there is common belief that pharmaceuticals are 
more expensive than in other countries. Payers are making use of this belief when 
negotiating prices with pharmaceutical companies. We wanted to know if there 
is scientific evidence for this conception. Methods: We conducted a systematic 
literature review in order to identify price comparison studies comparing Germany 
with at least three other countries. We searched Pudmed and six other databases 
to identify relevant articles published between 1998 and today. Furthermore we 
developed a quality rating tool based on the approaches from Andersson (1993) and 
Danzon/Kim (1998). Results: Our review delivered 4.927 articles from which 28 met 
our inclusion criteria. Study quality was quite heterogeneous, ranging from 3 to 13 
points with an average score of 8.8 out of 15. Some studies use old data back from 
1992 and no study considers the recent changes in German legislation (AMNOG). 
In addition no study includes rebates and selection of compared pharmaceuticals 
is often arbitrary. Reviewed studies report German pharmaceutical prices slightly 
above international average. High quality studies (upper quartile, quality score: 
> 9) find German prices below international average, whereas low quality studies 
(lower quartile, quality score: < 7) find German prices above international aver-
age. ConClusions: Results of the review suggest that there is a misconception of 
pharmaceutical pricing in Germany. Within a price comparison study any desired 
result can be achieved by deliberately choosing different approaches. At the end of 
the day payers and policy makers should stop comparing prices with other coun-
tries. Instead resources should better be spent on making value based reimbursment 
decisions in the respective health care setting.
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objeCtives: Since January 2012, Turkish government started to implement a man-
datory general health insurance law. The Social Security Institution (SSI) coverage 
which has been 86% in 2012 was expected to be 100% after this reform instead has 
declined to 82% in 2013. On the other hand, as Turkish Green Card Program - a state 
social scheme to ensure the provision of health services for the poor - was abolished 
and transferred from Ministry of Health to SSI, approximately 9 million people have 
been subject to income audit in order to be classified as eligible to pay premiums 
themselves and non-eligible ones for which the state will pay the premiums. In this 
regard; this poster presents this transformation and gives its current status in terms 
of contribution to Universal Health Coverage in Turkey. Methods: Publications of 
SSI, World Bank Reports and online articles are utilized. Results: The recent avail-
able data shows that 82% of the population is under the coverage of SSI. %2 of the 
population corresponds to the groups which are out of SSI coverage according to 
Law 5510, Article 60. Remaining population corresponds to 12 million people subject 
to income audit. Approximately 62% of those could not pass income audit and their 
premiums are paid by the state. ConClusions: Since 2012 there are increasing 
number of people taking income audit and have the capacity to pay premiums. It is 
also noteworthy to state that there were 8,865,470 people under Green Card scheme 
whereas after the transfer of Green Card to SSI; 11,357,306 people applied for the 
income audit in 2012, this reached to 12,266,043 people at the beginning of 2014. 
Findings show that as Green Card Scheme brought under SSI, coverage has been 
made available to all eligible people in a systematic and just way thus contributed 
the extent of coverage in Turkey.
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objeCtives: In early 2010, Greece was placed under International Supervision (EU, 
ECB and IMF), as a result of a growing public deficit and its non-sustainable state 
expenditure. At the time, the retail pharmaceutical market had a size of c. a. € 6.5 bn 
in retail prices (public pharmaceutical expenditure € 5.2 bn). Within that framework, 
prior and after the implementation of 5 selected policies of the HTP. The analysis 
was conducted for total imported pharmaceutical (IP) sales and total locally manu-
factured pharmaceutical (LMP) sales in the A0. The Durbin-Watson d statistics of 
SPSS version 20.0 was used as a test for serial correlation of error terms. Shift in 
slope with p< 0.05 was considered as statistically significant. Results: All policies 
effected the LMP sales more positively than IP sales except FP. However, the differ-
ence of impact was moderately positive for LMP sales, there was not any statisti-
cally significant change. ConClusions: Policy changes may effect at differently 
direction and amount the cost sales of LMPs and IPs. Non significant effect of these 
policy changes may partly explained by limited oberservation time and by other 
market dynamics.
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objeCtives: In 2003 Health Transformation Program and in 2006 Social Security 
Reform were launched in Turkey. At the end of the years 2009 and 2011 price cuts 
were done by the Government and between the years 2010-2012, there was a global 
budget implementation in Turkey. Health implications of these developments in the 
medicine market have not been analyzed in a comprehensive manner. The top 100 
medicines, annual average highest amount of sales of between 2008-2013, had one 
to four of the total pharmaceutical market value in 2013. In this study we aimed to 
determine these first 100 medicine’s, which have higher total sales amount, defining 
characteristics. Methods: While pharmaceutical sales data were obtained from 
the IMS Health-Turkey data base, characteristics of medicines were obtained from 
the Turkish Medicine And Medical Devices Agency and the Social Security Agency 
data bases. Results: While 78 medicines are original, 22 medicines are generic. 
60 medicines are imported medicines, 40 medicines are manufactured medicines. 
19 medicines are biotechnological medicines and all of these biotechnological 
medicines are original and imported. 96 medicines covered by Social Security pay-
ments. Equivalent of 65 medicines are available (each equivalent group from 1-30, 
an average of 13 generics available). 19 medicines and 15 medicines are respectively 
systemic anti-infectives and antineoplastics and immunomodulating agents. In 
this study, the license holders of the medicines are 40 firms in total. 15 firms have a 
market share of 75% and the medicines which, have 77,7% portion of total amount, 
are created by multinational firms. ConClusions: In the years which were the 
effects of reforms, price cuts and global budget implementation seen, the medicines 
which have higher total sales amount were mostly original, imported, covered by 
Social Security payments and created by multinational firms.
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objeCtives: Turkish Ministry of Health (MoH) initiated Health Transformation 
Program (HTP) in 2002. HTP impacted all clinical and economic outcomes of health 
including pharmaceutical sales by improving access to health services. The objective 
of this study is to understand the differences in the impact of selected 5 policies 
on 5 top selling ATC1 groups in terms of unit sales (US) in the respective peri-
ods. Methods: 132 months sales data with segmented regression analysis for 
interrupted time series were used. International reference pricing of pharmaceu-
ticals (RF), mandatory reimbursement dossier submission for new molecules, new 
indications and line extensions with medical and economic evaluations (MRDS), 
auditing for good manufacturing practice (GMP), family physician system (FP) and 
compulsory medical service for physicians (CMS) were selected as five major policies 
that may affect cost, demand and supply of pharmaceuticals. We analyzed possible 
breaks in trends prior and after the implementation of 5 selected policies of the 
HTP. The top 5 selling ATC1 groups were Systemic Antienfectives (J0), Cardiovascular 
System (C0), Alimentary and Metabolism (A0), Respiratory (R0) and Central Nerveous 
System (C0). The Durbin-Watson d statistics of SPSS version 20.0 was used as a test 
for serial correlation of error terms. Shift in slope with p< 0.05 was considered as 
statistically significant. Results: There was an increasing trend for all ATC1 groups 
prior the implementation of policies. The trends in J0 were negatively impacted from 
all policies except for RF. The C0 group was negatively impacted from all policies 
except for RF and CMS. The A0 group was positively impacted from all policies. The 
N0 was positively impacted from all policies except MRDS and FP. The R0 group was 
positively impacted from all policies except GMP and FP. ConClusions: Policy 
changes were not sufficient to control unit growth of top selling pharmaceutical 
groups. The effect of other policies to control unit sales of these group should also 
be evaluated.
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objeCtives: Turkey is using international reference pricing for the pharmaceu-
ticals. An update for Turkish pricing decree is published in April 2012 and price 
increases became more applicable due to various reasons. We analyzed price lists 
to identify pharmaceutical products that had any price increase in 2013 and defined 
causes in the decree Methods: We reviewed weekly cumulative price lists pub-
lished in Turkish Medicines and Medical Device Institution and compared each list 
with the list published in the previous week to identify products that had price 
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objeCtives: Medicine shortages are a global phenomenon. A growing number of 
reports indicate the problem is increasingly affecting the European pharmaceutical 
market. The present study aims to investigate the characteristics, determinants, 
legal aspects and management of medicine shortages in Belgium, France and from 
the perspective of the European Union. Methods: A review of scientific and grey 
literature was performed. The legal framework on European and national level 
was reviewed. Primary qualitative data was collected through 22 semi-structured 
interviews with key representatives of health care systems’ stakeholders on the 
national and European level. Results: France reported three times more shortages 
than Belgium. However, the main therapy area, the major cause and the dynamics 
of medicine shortages were analogous between the two countries. Determinants 
of medicine shortages were categorised in manufacturing problems, distribution 
and supply issues, and economic-related challenges. Manufacturing problems 
were most frequently reported as the primary cause of medicine shortages. Laws 
and regulations related to medicine shortages are more extensive in France than 
Belgium. Several preventive and responsive measures were identified to address 
such shortages. ConClusions: Although medicine shortages are country-specific, 
the underlying mechanisms of medicine shortages appear to be similar in Belgium 
and France. Economic aspects seem to play a central role in the phenomenon of 
medicine shortages, as it influences stakeholders’ business decisions. The impact 
of the legal framework around medicines on the occurrence of medicine shortages 
may be limited. Collaboration, communication and coordination are key to any 
effective approach to address medicine shortages.
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objeCtives: Firstly, to review whether medicines that have received expedited 
regulatory approval in the European Union (EU) subsequently received positive 
recommendations from selected Health Technology Assessment (HTA) agen-
cies in the EU. A second objective was to understand the reasons for negative 
appraisals of these medicines by EU HTA agencies. Methods: Medicines that 
have received Conditional Marketing Authorisation (CMA) by the European 
Medicines Agency (EMA) were identified from the EMA website. Websites of HTA 
agencies in the United Kingdom (NICE, SMC); Ireland (NCPE), France (HAS) and 
Germany (IQWiG) were searched to ascertain whether these medicines had been 
appraised. Appraisal reports were reviewed. For medicines with at least one nega-
tive appraisal, reason (s) for the negative appraisal were identified. Results: 
13 medicines have received CMA in the EU. 10 of these medicines have received 
a negative appraisal by at least one HTA agency (either ‘not recommended’ or 
deemed to offer ‘no additional benefit’ over existing treatment). Of the 10 medi-
cines with at least one negative appraisal, 8 are oncology medicines. The most 
common reason for a negative appraisal (relevant to 9 of the 10 medicines) was 
insufficient or uncertain clinical effectiveness. Uncertain cost-effectiveness in 
relation to the proposed treatment cost was mentioned as a source of uncertainty 
for 5 of the 10 medicines. ConClusions: Despite receiving expedited regulatory 
approval, patient access to innovative medicines in the EU may be delayed due 
to negative appraisal of these medicines by HTA agencies (most often due to a 
relative lack of data on clinical effectiveness). Such delays obviate the intention 
of expedited regulatory review of medicines.
PHP47
cHallenGes: in iMPleMenTinG HTa in THe reiMBurseMenT decisions in 
alGeria / a coMParTive analysis
Aissaoui A.1, Soualmi R.2, Kaddar M.3
1Paris dauphine University, Paris, France, 2Algiers University, Algiers, Algeria, 3Independant 
Consultant, Oran, Algeria
objeCtives: To provide a comprehensive description of the current Drug 
Reimbursement Systems in Algeria and to compare it to two archetypes drug reim-
bursement systems in France and UK and to a system in a middle income country: 
Turkey where the HTA has been recently implemented. Methods: We collected and 
reviewed relevant information to describe the health care and drug reimbursement 
systems in these countries; we reviewed the legal framework and procedure docu-
ments. For Algeria, in addition to the data and information collected, we conducted 
informal interviews supplemented by a survey among key stakeholders. Results: 
Compared to the UK, no similarities were found. This is probably due to the cultural 
differences and the lack of expertise in the use of cost-effectiveness approaches. 
Compared to the France, we didn’t find similarities, except the final decision which 
is taken at the Ministry level. This is due to the administrative nature and the lack 
of transparency of the assessment in Algeria especially where the methods as well 
as the results of the assessment are not explicitly expressed. Compared to Turkey, 
we found some similarities in terms of process, but not in terms of methods as this 
country is now more familiar with the HTA approach. ConClusions: Our study 
shows that the implementation of HTA differs according to cultural and financial 
factors and to expertise capacity in data collection, analysis and use in the decision 
making process. The use of HTA in the drug evaluation and reimbursement system 
in Algeria is underestimated and underdeveloped. That’s why before adopting HTA 
approaches in the pharmaceutical sector, the Algerian authorities should consider 
these factors and improve the data quality and decision process transparency. This 
is becoming vital as cost of drugs is increasing and the fiscal space will be more 
constrained in the near future.
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the reduction of pharmaceutical expenditure was one of the main targets for fiscal 
adjustment. The purpose of this study was to assess the usage of generic medicines 
in Greece, as a key driver for savings from the pharmaceutical market, and compare 
it with that of other major European countries. Methods: IMS data from several 
European countries was collected in terms of the overall retail pharmaceutical mar-
ket and the consumption of generic medicines in each of them. Focus was placed 
on the top-10 genericized molecules for Greece including alendronic acid, atorv-
astatin, carvedilol, clarithromycin, clopidogrel, donepezil, fluconazole, olanzapine, 
omeprazole and simvastatin. To ensure an “apples-to-apples” comparison across 
countries, the study focused on the retail market only (excluding hospitals) given 
that, in Greece, there is no publicly-available data for pharmaceutical consump-
tion within the hospital setting. Results: The analysis indicated that, in Greece, 
the penetration of generic medicines within the top-10 genericized molecules was 
65% in terms of volume, with off-patent medicines holding the remaining 35%. 
According to IMS data, Greece had a lower penetration of 21 percentage points 
(-24%) versus the weighted European average and -8.2 percentage points (-11%) 
versus the cluster of Southern European countries plus Ireland for calendar year 
2013. ConClusions: Generic penetration within the 10 largest genericized mol-
ecules, in Greek retail-pharmacy setting, is significantly lower versus the weighted 
average of major European countries but also compared to that of countries in 
similar economic situation with Greece.
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objeCtives: The practice of generic medicines prescribing, dispensing and 
substitution in developing countries has been controversial among health care 
professionals, particularly due to issues on quality, safety and efficacy. These con-
troversies are as a result of inter-country differences in policies and laws as well 
as individualized knowledge and attitudes of pharmacists pertaining to generic 
medicines. This study primarily aims to assess the knowledge, attitudes, and prac-
tices of community pharmacists in Qatar towards generic medicines. Methods: A 
cross-sectional study using a pretested paper-based survey was conducted among 
a random sample of community pharmacists in Qatar. The data were analyzed 
using IBM–SPSS® version 20. Both descriptive and inferential statistical analyses 
were applied. Results: A total of 160 surveys were distributed to community phar-
macists of which 118 were returned (response rate, 74%). The mean total score of 
generic medicines knowledge among the pharmacists was 6.8 ± 1.6 (maximum 
possible score was 10). Years of practice as well as place of obtaining academic 
degree did not influence knowledge score. Approximately 72% of the pharmacists 
supported generic substitution for brand name drugs in all cases where a generic 
medicine is available and the majority (93%) agreed that pharmacists should be 
given generic substitution right. Nearly 61% of the pharmacists considered lack 
of proven bioequivalence to original brands as an important barrier for selecting 
generic medicines and 55% rated “lack of policy for directing the practice of generic 
medicine” as an important barrier. ConClusions: In order to enhance the quality 
use of and to promote the practice of generic medicines in Qatar, an educational 
program should be implemented. A national generic medicine policy and guidelines 
are warranted in the State of Qatar.
PHP43
evaluaTinG raTes of PoTenTial Generic suBsTiTuTion for 
PrescriPTion druGs: can we iMProve on exisTinG incenTive scHeMes?
Walton S.1, Rash C.1, Lambert B.L.2, Galanter W.L.3
1University of Illinois at Chicago, Chicago, IL, USA, 2Northwestern, Chicago, IL, USA, 3University 
of Illinois Hospital and Health Sciences System, Chicago, IL, USA
objeCtives: Encouraging generic drug use has reduced health care costs for payers 
and consumers, but the rate of branded medications therapeutically interchange-
able to generic is not equal across medications disease states. The extent to which 
different systems of care are able to substitute towards generics is not well under-
stood. This study defined and measured the maximum generic rate (MGR) of cur-
rently prescribed drugs and illustrated differences across drugs associated with 
selected underlying diseases. Methods: Using information in prescription claims 
data, drugs were classified into “potentially generic substitutable” or not based on 
clinical consensus regarding the following algorithm: 1. They did not having have 
a narrow therapeutic index (NTI) as defined by the Food and Drug Administration 
(FDA); 2. Did not belong to one of six protected classes of drugs in Medicare D; 3. They 
were substitutable with a generic medication of the same chemical entity; 4. They 
were therapeutically interchangeable with a generic in the same class which was 
thought clinically to have class effect benefits and minimal risk of harm in switch-
ing. A maximum generic rate (MGR) was defined as the percent of prescriptions 
that could be generic. This rate was examined overall and across drugs known to 
be associated with illustrative diseases including hypertension, diabetes mellitus, 
and obstructive lung disease. Results: The MGR ranged from 100% for drugs used 
in hypertension to 26.7% for drugs used in obstructive lung disease. The overall 
maximum possible generic rate (MGR) was 83.6%. ConClusions: Payers wishing 
to promote generic substitution should incorporate the potential for substitution 
toward clinically appropriate generic medications as part of incentives for generic 
utilization to avoid unintended consequences of using a fixed target rate. A practical 
methodology for determining a MGR is offered here.
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